Pharmacology, Toxicology and Pharmaceutical Science
Rifampicin
100%
Mouse
88%
Isoniazid
69%
Mycobacterium Tuberculosis
63%
Rifapentine
45%
Pyrazinamide
45%
Clarithromycin
42%
Infection
36%
Moxifloxacin
36%
Chemotherapy
35%
Mouse Model
31%
Streptomycin
30%
Disease
29%
Clofazimine
28%
Ethambutol
24%
Mycobacterium ulcerans
23%
Ofloxacin
20%
Tuberculosis
19%
Buruli Ulcer
19%
Minocycline
16%
Lung Tuberculosis
16%
Antiinfective Agent
16%
HIV
16%
Experimental Tuberculosis
16%
Atypical Mycobacteriosis
15%
Tuberculostatic Agent
15%
Pharmacokinetics
15%
Combination Drug
15%
Clinical Trial
15%
Antibiotics
14%
Quinolone Derivative
14%
Murine
13%
Mycobacteria
13%
Mycobacterium leprae
13%
Bacilli
12%
Antibiotic Agent
12%
Dapsone
12%
Isoniazid Plus Rifampicin
12%
Drug Resistance
11%
Guinea Pig
11%
C57BL 6 Mouse
11%
Rifamycin
11%
Ranitidine
10%
Mycobacterium Avium Complex
10%
Rifabutin
10%
Sparfloxacin
9%
Vaccination Policy
9%
Pharmacodynamics
9%
Lepromatous Leprosy
8%
Pefloxacin
8%
Keyphrases
Tuberculosis
85%
Rifampin
49%
Clarithromycin
48%
Mycobacterium Leprae
38%
Pyrazinamide
37%
Rifampicin
35%
Mycobacterium Tuberculosis (M. tb)
34%
Mouse Model
26%
Rifapentine
24%
Moxifloxacin
22%
Clofazimine
22%
Dapsone
22%
Leprosy
22%
Mycobacterium Avium
21%
Chemotherapy
19%
Ethambutol
17%
Mycobacterium Avium Complex
16%
Mycobacterium Intracellulare
15%
Pulmonary Tuberculosis
15%
Lung
15%
Mycobacterium Ulcerans
15%
Streptomycin
15%
Short-course Chemotherapy
14%
Minocycline
14%
Antibiotics
14%
Experimental Tuberculosis
13%
Bacillus
12%
Mycobacterium
11%
Footpad
11%
Ofloxacin
11%
Rifabutin
11%
Clarithromycin Resistance
10%
Rifampicin Resistance
10%
Spleen
10%
Multibacillary
10%
AIDS/HIV
10%
Buruli Ulcer
9%
Sterilising Activity
9%
Drug Combination
9%
Tuberculosis Treatment
9%
Leprosy Patients
9%
Resistant mutants
8%
Murine Model
8%
High Dose
8%
Antimicrobial
7%
M. Ulcerans
7%
Amikacin
7%
Multibacillary Leprosy
7%
Monotherapy
7%
Sparfloxacin
7%
Immunology and Microbiology
Mouse
87%
Mycobacterium Tuberculosis
53%
Mycobacterium leprae
38%
Bactericidal Activity
35%
Mycobacterium Avium Complex
30%
Colony Forming Unit S
19%
Mouse Model
18%
Colony-Forming Unit
18%
Mycobacterium ulcerans
17%
Minimum Inhibitory Concentration
15%
Mycobacterium avium
14%
Bacilli
13%
Human Immunodeficiency Virus
11%
Mycobacteria
11%
Vaccination Policy
10%
Body Weight
10%
Drug Resistance
9%
Mycobacterium Bovis BCG
9%
Multi-Drug-Resistant Tuberculosis
9%
Drug Sensitivity
9%
Nude Mouse
9%
Macrophage
7%
C57BL 6 Mouse
7%
Nontuberculous mycobacteria
7%
Sputum
6%
Multidrug Resistance
6%
Bacteriology
5%
Mycobacterium xenopi
5%
Drug Megadose
5%
Acquired Immune Deficiency Syndrome
5%